Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 in generalized myasthenia gravis – long‑term safety and efficacy
CTR20220701Phase 3Completed
- Sponsor
- Harbour BioMed
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of batoclimab in myasthenia gravis (MG), sponsored by Harbour BioMed. Primary endpoint: Incidence of adverse events during the study. Started Mar 2022; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20220701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220701.